Canagliflozin (brand name Invokana) is a widely prescribed oral medication for the management of type 2 diabetes. As a member of the sodium-glucose cotransporter 2 (SGLT2) inhibitor class, it works by blocking glucose reabsorption in the kidneys, leading to increased glucose excretion in urine. This mechanism effectively lowers blood sugar levels independent of insulin secretion and has been shown to provide additional cardiovascular and renal benefits. However, like all potent therapies, SGLT2 inhibitors carry a risk of rare but serious adverse events. Among the most concerning is ketoacidosis, a metabolic emergency traditionally associated with type 1 diabetes but increasingly recognized in patients with type 2 diabetes taking these medications. Understanding this risk, recognizing its subtleties, and knowing how to respond are essential for anyone prescribed canagliflozin.

What Is Ketoacidosis? A Deeper Look

Ketoacidosis occurs when the body produces dangerously high levels of ketones — acidic byproducts of fat metabolism. Under normal conditions, cells rely on glucose for energy. When glucose availability is insufficient or when insulin levels are too low to facilitate glucose uptake, the body shifts to burning fatty acids instead. This metabolic switch generates ketone bodies (acetoacetate, beta-hydroxybutyrate, and acetone) as an alternative fuel source. In small amounts, ketones are harmless. But when production overwhelms the body's ability to clear them, the blood becomes acidic, leading to a cascade of physiological dysfunction.

In the context of diabetes, ketoacidosis is most often associated with type 1 diabetes and is termed diabetic ketoacidosis (DKA). Classic DKA typically presents with hyperglycemia (blood glucose often exceeding 250 mg/dL), metabolic acidosis, and elevated ketones. However, SGLT2 inhibitors like canagliflozin have introduced a variant known as euglycemic ketoacidosis, where significant acidosis occurs with blood glucose levels below 200 mg/dL. This atypical presentation makes diagnosis more challenging because the usual warning sign — high blood sugar — may be absent.

The physiological consequences of ketoacidosis are serious. Acidemia depresses cardiac contractility, impairs central nervous system function, and can lead to shock, cerebral edema, and death if not promptly treated. Even with modern intensive care, DKA carries a mortality rate of 1–5%, underscoring the importance of prevention and early detection.

Mechanism of Risk

The connection between canagliflozin and ketoacidosis stems from the drug's primary action. By increasing urinary glucose excretion, SGLT2 inhibitors lower plasma glucose levels, which in turn reduces the demand for endogenous insulin secretion. In some patients, particularly those with limited pancreatic beta-cell reserve, this can lead to a relative insulin deficiency. When insulin levels fall too low, the liver begins unrestrained ketogenesis — the production of ketones from fatty acids.

Additionally, canagliflozin has been shown to elevate glucagon levels, likely through direct effects on alpha cells in the pancreas. Glucagon stimulates hepatic ketogenesis, compounding the risk. The combination of reduced insulin and increased glucagon creates a metabolic environment primed for ketone overproduction, even when blood glucose levels remain normal or only mildly elevated.

Clinical Evidence and Incidence

The U.S. Food and Drug Administration (FDA) issued a safety communication in 2015 warning that SGLT2 inhibitors, including canagliflozin, were linked to cases of ketoacidosis requiring hospitalization. Subsequent analyses of adverse event reporting systems and clinical trials have refined our understanding. The FDA's label revisions now include explicit warnings about ketoacidosis for the entire class.

A meta-analysis published in the Journal of Diabetes Investigation estimated the incidence of ketoacidosis in SGLT2 inhibitor users at approximately 0.1–0.6 per 1,000 patient-years, compared to 0.1–0.2 per 1,000 patient-years with placebo or active comparators. While the absolute risk remains low, it represents a statistically significant increase. Importantly, a substantial proportion of reported cases — up to 70% in some series — occurred with euglycemic ketoacidosis, meaning blood sugar was not markedly elevated. This makes routine home glucose monitoring insufficient for detection.

Risk Factors That Amplify the Danger

Not everyone taking canagliflozin faces the same level of risk. Several predisposing conditions and situational factors significantly increase the likelihood of developing ketoacidosis:

  • Insulin deficiency or reduced beta-cell function: Patients with long-standing type 2 diabetes, low C-peptide levels, or a history of latent autoimmune diabetes in adults (LADA) are at higher risk.
  • Acute illness or infection: Fever, sepsis, pneumonia, or urinary tract infections increase metabolic stress and can trigger ketogenesis.
  • Major surgery or trauma: Perioperative fasting, stress, and altered insulin requirements create a perfect storm.
  • Very low carbohydrate or ketogenic diets: These diets independently promote ketosis, and adding an SGLT2 inhibitor can push the system into pathological ketoacidosis.
  • Alcohol or substance misuse: Alcohol metabolism shifts the redox state of the liver, favoring ketone production.
  • Dehydration or excessive fluid loss: Canagliflozin's diuretic effect can exacerbate volume depletion, further stimulating counter-regulatory hormones.
  • Insulin dose reduction or omission: Patients who lower their insulin too aggressively while on an SGLT2 inhibitor are vulnerable.
  • Reduced carbohydrate intake: Fasting, prolonged dietary restriction, or nausea causing poor intake can deplete glycogen stores and accelerate ketogenesis.

Recognizing the Warning Signs: A Different Presentation

The hallmark of canagliflozin-associated ketoacidosis is its subtlety. Because blood glucose levels may remain below 200 mg/dL, patients and even healthcare providers can dismiss early symptoms as a routine illness or medication side effect. The classic DKA triad — hyperglycemia, ketonemia, and acidosis — may be incomplete. It is critical to be aware of the following symptoms, especially when they occur in combination:

  • Nausea, vomiting, or abdominal pain: These are the most common presenting symptoms, often resembling gastritis or gastroenteritis.
  • Rapid, deep breathing (Kussmaul respirations): The body attempts to compensate for acidosis by blowing off carbon dioxide.
  • Extreme fatigue or lethargy: Acidemia depresses mitochondrial function and central nervous system activity.
  • Confusion or difficulty concentrating: Neurological effects can progress to stupor or coma.
  • Excessive thirst or dry mouth: Volume loss and hyperosmolality trigger these sensations.
  • Fruity-smelling breath: Acetone, a volatile ketone, produces a characteristic sweet odor.
  • Inappropriate lack of hyperglycemia: Blood sugar may be normal or only mildly elevated, creating false reassurance.

Any patient taking canagliflozin who develops persistent nausea, vomiting, or abdominal pain should seek immediate medical evaluation, with specific instruction to check for ketones and acidosis regardless of blood glucose level. Home urine ketone test strips can detect acetoacetate, but they may underestimate beta-hydroxybutyrate, the dominant ketone in DKA. Blood ketone meters (measuring beta-hydroxybutyrate) are more reliable.

Who Is at Highest Risk? Stratifying Patient Populations

While the absolute risk of ketoacidosis on canagliflozin is low, certain patient groups require heightened vigilance. Identifying these populations allows for more targeted counseling and monitoring.

Patients with Type 1 Diabetes or LADA

SGLT2 inhibitors are not approved for use in type 1 diabetes outside of limited clinical contexts, and their use in these patients carries the highest risk of ketoacidosis. Patients with latent autoimmune diabetes in adults (LADA) — sometimes misdiagnosed as type 2 — are also vulnerable because their beta-cell function declines over time. Checking C-peptide and autoantibody profiles (e.g., GAD-65) before starting therapy is advisable for patients with atypical features.

Patients on Low-Carbohydrate or Ketogenic Diets

Dietary ketosis from carbohydrate restriction, intermittent fasting, or very low-calorie diets is common. Combining such a diet with canagliflozin pushes the body toward pathological ketone accumulation. Patients should be educated about the interaction and advised to increase carbohydrate intake modestly if symptoms of ketosis develop.

Perioperative Patients

Surgery creates an ideal scenario for ketoacidosis: fasting, stress hormone release, and potential insulin omission. The FDA and the American Diabetes Association recommend holding SGLT2 inhibitors for at least 3–4 days before elective surgery. This window allows the drug to clear from the system and restores normal renal glucose handling. Patients should discuss any planned procedures with their healthcare team well in advance.

Patients with Reduced Kidney Function

Canagliflozin is not recommended for use in patients with an eGFR below 30 mL/min/1.73 m². As kidney function declines, the drug's glucose-lowering efficacy diminishes, but the risk of adverse events including dehydration and ketoacidosis persists. Regular monitoring of renal function is essential.

Preventive Strategies for Patients and Providers

Prevention is the most effective approach. Both patients and healthcare providers can take concrete steps to minimize the risk of ketoacidosis without abandoning the substantial benefits of canagliflozin therapy.

Patient Self-Management

  • Learn the symptoms of ketoacidosis, especially euglycemic ketoacidosis. Recognize that nausea, vomiting, and abdominal pain are red flags even when blood sugar is normal.
  • Have a sick-day plan. During illness, increase fluid intake, monitor blood glucose more frequently, and test for ketones (blood preferred) if symptoms arise. Know when to hold canagliflozin and when to call your doctor.
  • Stay hydrated. Drink at least 6–8 glasses of fluid daily. Dehydration amplifies ketosis.
  • Avoid prolonged fasting or extreme carbohydrate restriction. If you choose a low-carb diet, discuss this with your provider. Do not skip meals for extended periods.
  • Never stop insulin abruptly unless explicitly directed by your physician. Canagliflozin is an adjunct, not a replacement, for insulin therapy in those who require it.
  • Use medical alert identification. Wearing a medical ID bracelet that lists "SGLT2 inhibitor use" can help emergency personnel consider euglycemic ketoacidosis even if blood glucose is normal.

Provider Precautions

  • Screen for risk factors before prescribing. Assess beta-cell function (C-peptide), autoantibodies if indicated, dietary patterns, alcohol use, and history of pancreatitis.
  • Educate thoroughly. Provide written materials about ketoacidosis symptoms and the need to seek emergency care for persistent GI symptoms.
  • Implement a perioperative holding protocol. Withhold canagliflozin at least 3 days before surgery and resume only when oral intake and insulin status are stable.
  • Reassess therapy periodically. If a patient experiences any episode of ketoacidosis, discontinue the SGLT2 inhibitor permanently. Consider alternative agents.
  • Monitor kidney function and electrolyte status. Renal impairment alters drug clearance and risk profile.

What to Do If Symptoms Appear: A Step-by-Step Guide

Despite all precautions, symptoms may arise. Prompt action can distinguish a manageable event from a life-threatening one. Patients and caregivers should follow these steps:

  1. Stop taking canagliflozin immediately. Do not take the next dose until you have spoken with a healthcare professional.
  2. Test for ketones. Use a blood ketone meter if available. Urine test strips are a backup but less accurate for beta-hydroxybutyrate. A blood ketone level above 1.5 mmol/L is elevated; above 3.0 mmol/L is dangerous.
  3. Assess symptoms. If you have nausea, vomiting, abdominal pain, rapid breathing, or confusion, proceed directly to the emergency room — do not wait for an office appointment.
  4. Inform emergency staff of canagliflozin use. Tell them specifically that you are at risk for euglycemic ketoacidosis. Provide the name of the medication and the dose.
  5. Expect intravenous fluids, electrolyte replacement, and insulin. Treatment is similar to conventional DKA but may require higher glucose-containing fluids (e.g., dextrose solutions) due to the lack of hyperglycemia.
  6. Do not restart canagliflozin after an episode without explicit clearance from your endocrinologist or primary care provider. In most cases, the drug should be permanently discontinued.

Balancing Benefits Against Risks

It is important to contextualize the risk of ketoacidosis against the well-documented benefits of canagliflozin. The landmark CANVAS Program and CREDENCE trial demonstrated that canagliflozin reduces the risk of major adverse cardiovascular events, slows progression of diabetic kidney disease, and lowers heart failure hospitalizations. For many patients with type 2 diabetes and established cardiovascular disease or chronic kidney disease, these benefits outweigh the infrequent occurrence of ketoacidosis.

Risk mitigation does not mean avoidance of effective therapy. Rather, it calls for thoughtful patient selection, comprehensive education, and careful monitoring. The decision to use canagliflozin should be shared between patient and provider, grounded in an honest discussion of both the drug's advantages and its potential dangers.

Special Populations and Future Directions

Off-Label Use in Type 1 Diabetes

Despite the FDA not approving SGLT2 inhibitors for type 1 diabetes, some clinicians prescribe them off-label for patients struggling with glycemic control or obesity. This practice is controversial and carries a substantially higher ketoacidosis risk. Recent European trials using lower doses under strict protocols have shown modest benefit with careful monitoring, but the risk remains unacceptable in many cases. Patients with type 1 diabetes should not take canagliflozin outside of a research setting or specialist center with robust monitoring protocols.

Emerging Data on Preventive Strategies

Ongoing research is exploring whether baseline ketone monitoring, dietary adjustments, or dose reduction can lower ketoacidosis incidence. Preliminary evidence suggests that avoiding prolonged fasting and ensuring adequate carbohydrate intake during illness may be effective. Studies are also evaluating the role of continuous glucose monitors (CGMs) with ketone warning algorithms, though these are not yet standard.

The Role of Patient Support Programs

Pharmaceutical manufacturers and many healthcare systems offer patient education resources, including 24/7 hotlines for medication-related questions. Patients should utilize these services if they have concerns about symptoms or medication management. Additionally, online portals from organizations like the American Diabetes Association provide free, reliable information about diabetes medications and emergency preparedness.

Conclusion

Canagliflozin remains a valuable option in the diabetes armamentarium, offering glucose control, weight loss, and protection against cardiovascular and renal complications. However, its association with ketoacidosis — particularly the euglycemic variant — demands a high level of awareness. Patients must understand that normal blood sugar does not rule out ketoacidosis, and that gastrointestinal symptoms in particular warrant serious attention. With proper education, vigilant self-monitoring, and a strong partnership with their healthcare provider, patients can reap the benefits of canagliflozin while minimizing the risks. The key is not fear, but informed caution — a balanced approach that empowers patients to use this powerful therapy safely.

If you take canagliflozin, review this information with your doctor, create a sick-day plan, keep ketone testing supplies on hand, and never hesitate to seek advice when something feels off. Your safety depends on knowing what to watch for and acting quickly when it matters most.